You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Mallinckrodt
Merck
McKinsey

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

CUTAQUIG Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for CUTAQUIG

Identify potential brand extensions & biosimilar entrants

SponsorPhase
OctapharmaPhase 3

See all CUTAQUIG clinical trials

Recent Litigation for CUTAQUIG

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
PIECZENIK v. BAYER CORPORATION2010-05-04

See all CUTAQUIG litigation

Patent Text Search: US Patents for CUTAQUIG

These patents were identified by searching patent claims

Supplementary Protection Certificates for CUTAQUIG

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C 2018 019 Romania   Start Trial PRODUCT NAME: PADELIPORFIN; NATIONAL AUTHORISATION NUMBER: EU/1/17/1228; DATE OF NATIONAL AUTHORISATION: 20171110; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1228; DATE OF FIRST AUTHORISATION IN EEA: 20171110
122018000045 Germany   Start Trial PRODUCT NAME: PADELIPORFIN IN DER FORM SEINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES MIT EINEM EINWERTIGEN KATION, INSBESONDERE DAS DIKALIUMSALZ; REGISTRATION NO/DATE: EU/1/17/1228 20171110
2018/016 Ireland   Start Trial PRODUCT NAME: PADELIPORFIN AS A DIPOTASSIUM SALT; REGISTRATION NO/DATE: EU/1/17/1228 20171110
2018C/018 Belgium   Start Trial PRODUCT NAME: TOOKAD - PADELIPORFIN WAARBIJ PADELIPORFIN IN DE VORM VAN HET DIKALIUMZOUT IS ; AUTHORISATION NUMBER AND DATE: EU/1/17/1228 20171114
CR 2018 00018 Denmark   Start Trial PRODUCT NAME: PADELIPORFIN DIPOTASSIUM SALT; REG. NO/DATE: EU/1/17/1228 20171114
C201830022 Spain   Start Trial PRODUCT NAME: PADELIPORFINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1228; DATE OF AUTHORISATION: 20171110; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1228; DATE OF FIRST AUTHORISATION IN EEA: 20171110
300934 Netherlands   Start Trial PRODUCT NAME: PADELIPORFINE (ALS DI-KALIUM ZOUT); REGISTRATION NO/DATE: EU/1/17/1228 20171110
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
AstraZeneca
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.